Compare ORMP & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORMP | STIM |
|---|---|---|
| Founded | 2002 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.3M | 120.4M |
| IPO Year | 2010 | 2018 |
| Metric | ORMP | STIM |
|---|---|---|
| Price | $4.69 | $2.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 198.5K | ★ 1.2M |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | ★ 412.50 | 57.25 |
| EPS | ★ 2.76 | N/A |
| Revenue | $2,000,000.00 | ★ $52,776,000.00 |
| Revenue This Year | N/A | $11.10 |
| Revenue Next Year | N/A | $11.92 |
| P/E Ratio | $1.68 | ★ N/A |
| Revenue Growth | ★ 49.25 | N/A |
| 52 Week Low | $2.09 | $0.80 |
| 52 Week High | $5.47 | $3.44 |
| Indicator | ORMP | STIM |
|---|---|---|
| Relative Strength Index (RSI) | 46.12 | 50.27 |
| Support Level | $3.91 | $2.67 |
| Resistance Level | $5.10 | N/A |
| Average True Range (ATR) | 0.20 | 0.20 |
| MACD | -0.07 | -0.05 |
| Stochastic Oscillator | 8.70 | 22.88 |
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.